Magdala Paul
Hollywood, FLNPI 1992103469
Payments from drug & device makers
Across 84 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$182
- Lilly USA, LLC$171
- Novo Nordisk$157
- AstraZeneca$145
- Sumitomo Pharma America, Inc.$120
- Amgen$115
- plus $779 from 19 others
What the payments were for
- Food & beverage$1,669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $182 |
| Lilly USA, LLC | 10 | $171 |
| Novo Nordisk | 8 | $157 |
| AstraZeneca | 8 | $145 |
| Sumitomo Pharma America, Inc. | 5 | $120 |
| Amgen | 7 | $115 |
| Abbott | 5 | $101 |
| Insmed, Inc. | 4 | $76 |
| Exact Sciences | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $69 |
| Astellas Pharma US Inc | 2 | $51 |
| GSK | 3 | $46 |
| Boehringer Ingelheim | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| AbbVie | 2 | $37 |
| Dexcom, Inc. | 2 | $35 |
| Eisai Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $27 |
| Gilead | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Eagle Pharmaceuticals, Inc. | 1 | $20 |
| CSL Behring | 1 | $17 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $125,544 |
| DescovyEmtricitabine/Tenofov Alafenam | 73 | $124,079 |
| RybelsusSemaglutide | 24 | $26,297 |
| MounjaroTirzepatide | 16 | $16,365 |
| OzempicSemaglutide | 21 | $14,535 |
| FarxigaDapagliflozin Propanediol | 12 | $7,862 |
| Repatha SureclickEvolocumab | 11 | $5,873 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 42 | $2,572 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,957 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,357 |
| Atorvastatin Calcium | 70 | $542 |
| Ventolin HfaAlbuterol Sulfate | 13 | $541 |
| Losartan Potassium | 31 | $408 |
| Gabapentin | 31 | $358 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $26 | $249,623107 claims |
| Novo NordiskRybelsus, Ozempic | $157 | $40,83345 claims |
| Lilly USA, LLCMounjaro | $171 | $16,36516 claims |
| AstraZenecaFarxiga | $145 | $7,86212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.